Clinical trials: Immunocompromised Patients
Rabies Exposure, Immunocompromised
Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations
This study adopts a parallel-controlled design and includes a study group and a control group. The study group will enroll 150 special population participants (including non-HIV-related immunocompromised individuals, patients…
- Conditions
- Rabies Exposure, Immunocompromised, Chronic Disease
- Trial name
- NCT07120464
- Testing
- Observation Only
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Hematological Malignancies, Cancer
Cologne Cohort of Neutropenic Patients (CoCoNut)
The Cologne Cohort of Neutropenic Patients (CoCoNut) is a non-interventional cohort study assessing risk factors, interventions, and outcome of immunosuppressed patients with or without opportunistic infections.
- Conditions
- Hematological Malignancies, Cancer, Chemotherapy, Neutropenia
- Trial name
- CoCoNut (NCT01821456)
- Testing
- Antiinfectives
- Where
- Germany
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- University Hospital of Cologne
Human Papilloma Virus, Hiv
Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients
Patients with immunodeficiencies are at increased risk of developing persistent HPV infection and as such HPV-related disease (genital warts and cancer).
- Conditions
- Human Papilloma Virus, Hiv, Organ Transplants
- Trial name
- NCT03525210
- Testing
- 9-valent HPV vaccine
- Where
- Belgium
- Volunteers
- 271 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
COVID-19
Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
Sotrovimab binds to a conserved epitope on the severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike protein outside the receptor-binding motif and has been shown to reduce the risk of hospitalization…
- Trial name
- LUNAR (NCT05305651)
- Testing
- Sotrovimab
- Where
- 8 sites in United Kingdom
- Volunteers
- 217 people
- Sponsor
- GlaxoSmithKline
Immunocompromised Patients and Non-immunosuppressed Patients at Risk With an Indication for Pneumococcal Vaccination
Evaluation of Pneumococcal Vaccine Coverage
Pneumococcal infections are frequent and serious. Streptococcus pneumoniae is the leading cause of community-acquired pneumonia in adults.
- Trial name
- SAUVAC (NCT03597269)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Immunodeficiency and Suspected Infection
Evaluation of High Throughput Sequencing for Screening of Pathogens in Immunocompromised Patients With Suspected Infectious Disease.
The study patients are patients suffering from primary or secondary immunodeficiencies investigated in the Hospital Necker for a suspected infectious disease.
- Trial name
- PATHOQUEST1 (NCT02007642)
- Testing
- Blood sampling / Body fluid sampling
- Where
- 2 sites in France
- Volunteers
- 250 people
- Sponsor
- Pathoquest
BK Polyomavirus
Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients
This is a pilot study using cytotoxic T lymphocytes (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Gamma-capture system will be effective in decreasing specific viral load in patients with BK virus viremia and BK…
- Trial name
- BK-CTLs (NCT04293042)
- Testing
- BK-virus specific CTLs
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital of Philadelphia
COVID-19, COVID-19 (SARS-CoV-2 Infection)
Evaluation of the Safety and Efficacy of Autologous COVID-19 Antigen Specific T Cell in Prolonged SARS-CoV-2 Patients
The goal of this clinical study is to evaluate the safety and efficacy of autologous COVID-19 antigen specific T cell (LB-DTK-COV19) treatment in prolonged SARS-CoV-2 infected patients.
- Trial name
- NCT07690943
- Testing
- LB-DTK-COV19
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- LucasBio
Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure
Shingrix in Renal Transplant Recipients
The goal of this clinical trial is to learn how well the shingles vaccine (Shingrix) works and how safe it is in adults with kidney failure who are waiting for a kidney transplant, including those who later receive a transplant.
- Conditions
- Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure, Kidney Failure, Chronic, Kidney Transplantation
- Trial name
- NCT04128189
- Testing
- Shingrix
- Where
- 4 sites in United States
- Volunteers
- 132 people
- Sponsor
- University of Colorado, Denver
Immunodeficiency, Immunosuppression
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
The investigators will examine whether a combination of at-home nucleic acid amplification tests, on-demand telemedicine, and delivery of prescriptions such as Paxlovid quickly after testing positive for COVID-19, can reduce…
- Conditions
- Immunodeficiency, Immunosuppression, HIV Infections, Graft Versus Host Disease
- Trial name
- NCT05655546
- Testing
- Access to Cue Health COVID-19 Remote testing and treatment for COVID-19
- Where
- United States
- Volunteers
- 2,117 people
- Sponsor
- Scripps Translational Science Institute
Tuberculosis, Monitoring, Immunologic
T Cell Interferon-gamma Release Assay (TIGRA) in Immunocompromised Individuals
Until recently, the tuberculin skin test (TST) was the only available diagnostic assay for detection of latent infection with M. tuberculosis (LTBI).
- Trial name
- TBNET-TIPS (NCT00707317)
- Where
- 21 sites in Australia, Bulgaria and 12 more
- Volunteers
- 1,843 people, healthy volunteers welcome
- Sponsor
- Tuberculosis Network European Trialsgroup
Respiratory Syncytial Virus Infection
Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®
This post marketing observational study (PMOS) was conducted in Japan during the 2013-2014 and 2014-2015 Respiratory Syncytial Virus (RSV) seasons to assess the safety and effectiveness of palivizumab for the prevention of…
- Trial name
- NCT02016690
- Volunteers
- 312 people
- Sponsor
- AbbVie
Immuno-modulation, Immuno-suppression
Analysis of the Specificity and Persistence of Nasal Immune Responses to Respiratory Viral Antigens in Immunocompromised and Healthy Cohorts
The goal of this observational study is to characterize nasal mucosal immunity to respiratory viruses, such as SARS-CoV-2, in immunocompromised individuals and healthy volunteers.
- Conditions
- Immuno-modulation, Immuno-suppression, Immunocompromised Patients, Healthy Subjects
- Trial name
- NCT07295535
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Invasive Fungal Disease, Critical Illness
De-escalation - Antifungal Treatment Immunocompromised Patients
A small proportion of intensive care unit patients receiving antifungals have a proven invasive fungal infection. However, antifungal treatment has side effects such as toxicity, emergence of resistance, and high cost.
- Trial name
- D-ATFIM (NCT03774316)
- Where
- France
- Volunteers
- 275 people
- Sponsor
- University Hospital, Lille
Primary or Secondary Immune Deficiency Including Immunosuppressive Therapy, Chemotherapy, HIV Infection
Performance of Clinical Metagenomics in Stool and Urine Samples for Unexplained Diseases Diagnostic and Emerging Diseases Surveillance in Immunocompromised Patients
The study is based on the hypothesis that the concomitant use of mNGS in non-invasive samples (stool, urine) could improve the rate of detected pathogens in immunodeficient patients compared with mNGS performed in an invasive…
- Trial name
- SENTINEL (NCT07603453)
- Testing
- Metagenomics
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV-1-infection, Cancer
Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)
CORIA is an observational cohort study of immunosuppressed populations who test positive for COVID-19. This includes people living with HIV, cancer, acquired immunodeficiency associated with other immunosuppressive therapy…
- Conditions
- HIV-1-infection, Cancer, Primary Immune Deficiency Disorder, Immunosuppression Disorders
- Trial name
- CORIA (NCT04354818)
- Where
- 11 sites in Australia
- Volunteers
- 27 people
- Sponsor
- Kirby Institute
Respiratory Syncytial Virus
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
The study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adults aged ≥18 to <60 years.
- Trial name
- NCT06067230
- Testing
- mRNA-1345
- Where
- 44 sites in United States, Canada and 2 more
- Volunteers
- 1,153 people
- Sponsor
- ModernaTX, Inc.
Respiratory Syncytial Virus Infections
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
This study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.
- Trial name
- NCT07092865
- Testing
- Adjuvanted RSVPreF3 vaccine
- Where
- 38 sites in United States, Australia and 6 more
- Volunteers
- 168 people
- Sponsor
- GlaxoSmithKline
COVID-19, Immunosuppressed Host
COVID-19 Infection in Patients Receiving Anti-CD20 Therapy
This study is being conducted to determine if patients with compromised B-cell function due to anti-CD20 therapy and newly diagnosed COVID-19 infection benefit from convalescent plasma.
- Conditions
- COVID-19, Immunosuppressed Host, Convalescent Plasma, Anti-CD20 Therapy
- Trial name
- NCT04884477
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 342 people
- Sponsor
- Mayo Clinic
Influenza
Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season
This a sub-study of a 5-year study designed to investigate how antibody and T cell responses following influenza vaccine compare among lung transplant patients, patients waiting for lung transplantation, and healthy individuals.
- Trial name
- NCT04530786
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison